Open Veils
AboutBrowse

Open Veils · Answer

What mRNA vaccines are currently being given to dogs?

At least two RNA-platform canine vaccines are now commercially deployed in the U.S.: Merck's Nobivac NXT (a self-amplifying RNA product for canine influenza H3N2/H3N8) and a Zoetis mRNA flu product pending broader U.S. rollout. A saRNA rabies vaccine — LVRNA001, also from Merck — received approval in Canada in 2024 and may enter U.S. clinics imminently. FOIA data obtained by The HighWire (April 2026) reveal 296 adverse-event cases tied to Nobivac NXT in under a year of post-market surveillance, including 152 adverse reactions and 76 lack-of-efficacy reports where vaccinated dogs still developed respiratory illness.

Evidence

  • Nobivac NXT Canine Flu (Merck Animal Health) is the first widely used saRNA product on the U.S. pet market, licensed for both H3N2 and H3N8 strains.
  • A second platform product, Nuvaxys Canine Flu from Zoetis, uses the same lipid-nanoparticle delivery system as human COVID-19 mRNA vaccines and is licensed in several EU countries, with U.S. approval pending.
  • The HighWire (April 2026), citing FOIA documents from the USDA covering September 2024 through July 2025, reported 1,888 total pages of adverse-event filings for Nobivac NXT alone — the first 1,012 pages reviewed showed 296 suspect cases.
  • Merck's saRNA rabies vaccine (LVRNA001) is already commercially available in Canada and was described by veterinarian Angie Krause (Oct 2026) as an imminent U.S. arrival.
  • Per Today's Veterinary Practice (Feb 2026), saRNA differs from conventional LNP-encapsulated mRNA in that the RNA strand self-replicates inside cells, theoretically requiring a lower initial dose — a mechanism previously deployed only in swine influenza programs before its canine rollout.

Ask your own question

Related questions

Share this answer